• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

/- 突变型肺癌：向临床冲刺？

/-Mutant Lung Cancer: Racing to the Clinic?

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

出版信息

Clin Cancer Res. 2018 Mar 15;24(6):1243-1245. doi: 10.1158/1078-0432.CCR-17-3597. Epub 2018 Jan 17.

DOI:10.1158/1078-0432.CCR-17-3597
PMID:29343556
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5856629/
Abstract

Although mutation of has been described in non-small cell lung cancer (NSCLC), co-mutation with , another Ras-GTPase activating protein (RasGAP), defines a novel genetically defined subclass of NSCLC. /-mutant cell lines are highly sensitive to MEK inhibitors, warranting clinical evaluation of MAPK inhibition in this subclass of patients. .

摘要

虽然 突变已在非小细胞肺癌（NSCLC）中被描述，但与另一种 Ras-GTP 酶激活蛋白（RasGAP） 共突变定义了 NSCLC 的一个新的遗传定义亚类。/-突变细胞系对 MEK 抑制剂高度敏感，这使得在该亚类患者中评估 MAPK 抑制具有临床意义。

相似文献

1
/-Mutant Lung Cancer: Racing to the Clinic?/- 突变型肺癌：向临床冲刺？
Clin Cancer Res. 2018 Mar 15;24(6):1243-1245. doi: 10.1158/1078-0432.CCR-17-3597. Epub 2018 Jan 17.
2
and are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition.和 优先发生共突变，并定义了对 MEK 抑制敏感的与吸烟相关的非小细胞肺癌的一个独特遗传亚群。
Clin Cancer Res. 2018 Mar 15;24(6):1436-1447. doi: 10.1158/1078-0432.CCR-17-2343. Epub 2017 Nov 10.
3
Generation of mice with a conditional allele of the p120 Ras GTPase-activating protein.具有p120 Ras GTP酶激活蛋白条件等位基因的小鼠的产生。
Genesis. 2007 Dec;45(12):762-7. doi: 10.1002/dvg.20354.
4
Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.NF1 突变型肺癌的临床和分子特征
Clin Cancer Res. 2016 Jul 1;22(13):3148-56. doi: 10.1158/1078-0432.CCR-15-2377. Epub 2016 Feb 9.
5
New Driver Mutations Detected in NSCLC.新的非小细胞肺癌驱动基因突变被检测到。
Cancer Discov. 2016 Aug;6(8):809. doi: 10.1158/2159-8290.CD-NB2016-074. Epub 2016 Jun 13.
6
Cutting Edge: Codeletion of the Ras GTPase-Activating Proteins (RasGAPs) Neurofibromin 1 and p120 RasGAP in T Cells Results in the Development of T Cell Acute Lymphoblastic Leukemia.前沿：T细胞中Ras GTP酶激活蛋白（RasGAPs）神经纤维瘤蛋白1和p120 RasGAP的共同缺失导致T细胞急性淋巴细胞白血病的发生。
J Immunol. 2015 Jul 1;195(1):31-5. doi: 10.4049/jimmunol.1402639. Epub 2015 May 22.
7
Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation.RASA1 的失活通过 R-Ras 激活促进黑色素瘤的肿瘤发生。
Oncotarget. 2016 Apr 26;7(17):23885-96. doi: 10.18632/oncotarget.8127.
8
KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.KRAS 突变型肺癌细胞对 MEK 抑制剂的反应因 AKT 或 STAT3 的激活而不同：对联合治疗方法的启示。
Mol Carcinog. 2010 Apr;49(4):353-62. doi: 10.1002/mc.20607.
9
Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.粘着斑激酶调节DNA损伤反应，其抑制作用可使突变型KRAS肺癌对放疗敏感。
Clin Cancer Res. 2016 Dec 1;22(23):5851-5863. doi: 10.1158/1078-0432.CCR-15-2603. Epub 2016 May 24.
10
RasGTPase-activating protein is a target of caspases in spontaneous apoptosis of lung carcinoma cells and in response to etoposide.RasGTP酶激活蛋白是肺癌细胞自发凋亡以及对依托泊苷反应过程中半胱天冬酶的作用靶点。
Carcinogenesis. 2004 Jun;25(6):909-21. doi: 10.1093/carcin/bgh075. Epub 2004 Jan 23.

引用本文的文献

1
A Systematic Analysis of Expression and Function of RAS GTPase-Activating Proteins (RASGAPs) in Urological Cancers: A Mini-Review.泌尿系统癌症中RAS鸟苷三磷酸酶激活蛋白（RASGAPs）表达与功能的系统分析：一篇综述短文
Cancers (Basel). 2025 Apr 28;17(9):1485. doi: 10.3390/cancers17091485.
2
Plasma-Activated Medium Inhibited the Proliferation and Migration of Non-Small Cell Lung Cancer A549 Cells in 3D Culture.等离子体激活培养基抑制三维培养中非小细胞肺癌A549细胞的增殖和迁移。
Int J Mol Sci. 2024 Dec 10;25(24):13262. doi: 10.3390/ijms252413262.
3
From pathogenesis to treatment: the impact of bacteria on cancer.

本文引用的文献

1
and are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition.和 优先发生共突变，并定义了对 MEK 抑制敏感的与吸烟相关的非小细胞肺癌的一个独特遗传亚群。
Clin Cancer Res. 2018 Mar 15;24(6):1436-1447. doi: 10.1158/1078-0432.CCR-17-2343. Epub 2017 Nov 10.
2
Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.达拉非尼联合曲美替尼治疗既往未经治疗的 BRAF 突变型转移性非小细胞肺癌的开放标签、2 期临床试验。
Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.
3
从发病机制到治疗：细菌对癌症的影响
Front Microbiol. 2024 Sep 18;15:1462749. doi: 10.3389/fmicb.2024.1462749. eCollection 2024.
4
Lack of imbalance between the master regulators TTF1/NKX2-1 and ΔNp63/p40 implies adverse prognosis in non-small cell lung cancer.主调控因子 TTF1/NKX2-1 和 ΔNp63/p40 之间的失衡暗示非小细胞肺癌的预后不良。
Sci Rep. 2024 Jan 30;14(1):2467. doi: 10.1038/s41598-024-52776-z.
5
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS.靶向小分子 GTP 酶：KRAS 开创的针对先前无法控制的靶点的新兴方法。
Signal Transduct Target Ther. 2023 May 23;8(1):212. doi: 10.1038/s41392-023-01441-4.
6
Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in and p.R461* in Genes-A Case Report with Literature Review.达拉非尼联合曲美替尼治疗 基因 p.D594G 错义突变和 p.R461* 无义突变的肺鳞癌一例报告并文献复习
Int J Mol Sci. 2023 Jan 7;24(2):1195. doi: 10.3390/ijms24021195.
7
Altered expression of ACOX2 in non-small cell lung cancer.ACOX2 在非小细胞肺癌中的表达改变。
BMC Pulm Med. 2022 Aug 23;22(1):321. doi: 10.1186/s12890-022-02115-7.
8
Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.表皮生长因子受体突变型肺癌患者中 NF1 突变的预后特征和全面基因组分析。
Cancer Med. 2023 Jan;12(1):396-406. doi: 10.1002/cam4.4925. Epub 2022 Jun 14.
9
Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities.组合性肿瘤抑制因子失活可有效引发具有治疗弱点的肺腺癌。
Cancer Res. 2022 Apr 15;82(8):1589-1602. doi: 10.1158/0008-5472.CAN-22-0059.
10
Tumorigenic bacteria in colorectal cancer: mechanisms and treatments.结直肠癌中的致瘤细菌：机制与治疗
Cancer Biol Med. 2021 Sep 30;19(2):147-62. doi: 10.20892/j.issn.2095-3941.2020.0651.
Inflammation as a driver and vulnerability of KRAS mediated oncogenesis.
炎症作为KRAS介导的肿瘤发生的驱动因素和脆弱点。
Semin Cell Dev Biol. 2016 Oct;58:127-35. doi: 10.1016/j.semcdb.2016.06.009. Epub 2016 Jun 11.
4
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.一例携带MET剪接位点突变的肺腺癌患者对克唑替尼的反应
Clin Lung Cancer. 2015 Sep;16(5):e101-4. doi: 10.1016/j.cllc.2015.01.009. Epub 2015 Feb 7.
5
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.一项将MEK1/MEK2抑制剂曲美替尼（GSK1120212）与多西他赛对比用于KRAS突变的晚期非小细胞肺癌（NSCLC）的随机II期研究†。
Ann Oncol. 2015 May;26(5):894-901. doi: 10.1093/annonc/mdv072. Epub 2015 Feb 26.